Tirzepatide is a new generation medication for weight loss, obesity treatment, and diabetes mellitus treatment.
It is a dual agonist of GIP and GLP-1 receptors, unlike Ozempic, which is only a GLP-1 agonist.
The drug was officially approved by the FDA (USA) in 2022 for the treatment of obesity and type 2 diabetes. In Europe, it was approved in 2023.
A double blow against obesity:
Activation of GLP-1 receptors
suppresses glucagon secretion, which raises blood sugar levels,
slows gastric emptying leading to a slower entry of glucose into the bloodstream, and
affects satiety centers in the hypothalamus, reducing appetite and increasing the feeling of fullness.
This promotes weight loss.
Activation of GIP receptors (the main difference compared to isolated GLP-1 analogs)
potentiates the effects of GLP-1 and improves the metabolism of fat cells (adipocytes).
Synergistic effect:
The combination of two mechanisms in a single molecule provides a more potent effect on blood glucose levels and body weight compared to isolated GLP-1 class drugs (e.g., semaglutide, liraglutide).
Tirzepatide is a new generation medication for weight loss, obesity treatment, and diabetes mellitus treatment.
It is a dual agonist of GIP and GLP-1 receptors, unlike Ozempic, which is only a GLP-1 agonist.
The drug was officially approved by the FDA (USA) in 2022 for the treatment of obesity and type 2 diabetes. In Europe, it was approved in 2023.
A double blow against obesity:
Activation of GLP-1 receptors
suppresses glucagon secretion, which raises blood sugar levels,
slows gastric emptying leading to a slower entry of glucose into the bloodstream, and
affects satiety centers in the hypothalamus, reducing appetite and increasing the feeling of fullness.
This promotes weight loss.
Activation of GIP receptors (the main difference compared to isolated GLP-1 analogs)
potentiates the effects of GLP-1 and improves the metabolism of fat cells (adipocytes).
Synergistic effect:
The combination of two mechanisms in a single molecule provides a more potent effect on blood glucose levels and body weight compared to isolated GLP-1 class drugs (e.g., semaglutide, liraglutide).